All Updates

All Updates

icon
Filter
Funding
Molecule.one raises USD 4.6 million in a seed funding round
AI Drug Discovery
Jun 1, 2021
This week:
Product updates
Nintendo ventures into MMOs with new Switch Online game playtest
Metaverse Experience Platforms
Yesterday
Product updates
HP releases texture library for 3D printing with CoreTechnologie 4D Additive
Additive Manufacturing
Oct 21, 2024
Partnerships
Honeywell partners with Google to bring Gemini AI to industrial sector
Smart Factory
Oct 21, 2024
Product updates
xAI launches API for third-party developers to access Grok models
Foundation Models
Oct 21, 2024
Partnerships
Nava Benefits partners with OpenAI to launch AI-powered benefits assistant
Foundation Models
Oct 21, 2024
Product updates
IBM releases Granite 3.0 AI models for enterprise use
Foundation Models
Oct 21, 2024
Partnerships
Honeywell partners with Google to bring Gemini AI to industrial sector
Foundation Models
Oct 21, 2024
M&A
Inflection AI acquires Boundaryless for undisclosed sum to accelerate enterprise AI deployments
Foundation Models
Oct 21, 2024
Industry news
News Corp sues Perplexity AI for alleged copyright infringement
Generative AI Applications
Oct 21, 2024
Product updates
Haiper debuts new video generation model
Generative AI Applications
Oct 21, 2024
AI Drug Discovery

AI Drug Discovery

Jun 1, 2021

Molecule.one raises USD 4.6 million in a seed funding round

Funding

  • Molecule.one, a Poland-based artificial intelligence (AI) drug design and molecule synthesis startup, has raised USD 4.6 million in a seed funding round led by Atmos Ventures, with the participation of various other investors.

  • The proceeds will be used for the company’s expansion purposes, including growing the team and opening new offices in the US and Western Europe. The company is also focused on continually adding features to its AI platform, which creates theoretical molecular pathways and enables synthesis planning.

  • Founded in 2016, Molecule.one operates a cloud-based computational chemistry platform that assists drug developers in accelerating the discovery process by leveraging AI to design synthesis pathways and create molecules. The company was the first startup from the Central and Eastern European region to pitch at the TechCrunch Startup Battlefield in 2019.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.